HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.

AbstractBACKGROUND:
Optimal surgical management of patients with invasive lobular carcinoma (ILC) who undergo neoadjuvant chemotherapy (NAC) is unknown. We evaluated optimal margin distance and local recurrence (LR) rates for these patients.
METHODS:
Ninety-three (30%) of 311 patients with ILC received NAC. We examined margin status, residual disease after re-excision, and clinical outcomes.
RESULTS:
Margin positivity rates after the final operative procedure were similar between the NAC and surgery-first group (P > .05). The proportion of patients, stratified by margin status, who were taken back for re-excision was not different between the 2 groups, and, similarly, there were no differences in frequency of residual disease (all P > .05). At a median follow-up of 3.1 years, 1 patient in the NAC group and 2 in the surgery-first group developed LR (P = 1.0).
CONCLUSIONS:
Patients with ILC who have undergone NAC and have margins >1 mm have a low probability of residual disease and LR.
AuthorsJamie Wagner, Judy C Boughey, Betsy Garrett, Gildy Babiera, Henry Kuerer, Funda Meric-Bernstam, Eva Singletary, Kelly K Hunt, Lavinia P Middleton, Isabelle Bedrosian
JournalAmerican journal of surgery (Am J Surg) Vol. 198 Issue 3 Pg. 387-91 (Sep 2009) ISSN: 1879-1883 [Electronic] United States
PMID19362281 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms (drug therapy, pathology, surgery)
  • Carcinoma, Lobular (drug therapy, pathology, surgery)
  • Chemotherapy, Adjuvant
  • Chi-Square Distribution
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual (drug therapy, pathology, surgery)
  • Reoperation
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: